|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-10-25
|
|
pubmed:abstractText |
Bexarotene (Targretin oral capsules), the first RXR-selective retinoid "rexinoid" approved for all stages of cutaneous T-cell lymphoma (CTCL), had a response rate (RR) of 45% at the optimal dose of 300 mg/m(2) per day in 2 multicenter trials. With hypertriglyceridemia reported at 79%, bexarotene is often administered with lipid-lowering agents (LLAs). Statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) may modulate class II major histocompatibility class expression and T-cell responses.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0190-9622
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
672-84
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12399758-Algorithms,
pubmed-meshheading:12399758-Anticarcinogenic Agents,
pubmed-meshheading:12399758-Dermatitis, Exfoliative,
pubmed-meshheading:12399758-Drug Therapy, Combination,
pubmed-meshheading:12399758-Female,
pubmed-meshheading:12399758-Humans,
pubmed-meshheading:12399758-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:12399758-Hypertriglyceridemia,
pubmed-meshheading:12399758-Hypothyroidism,
pubmed-meshheading:12399758-Middle Aged,
pubmed-meshheading:12399758-Mycosis Fungoides,
pubmed-meshheading:12399758-Photopheresis,
pubmed-meshheading:12399758-Prospective Studies,
pubmed-meshheading:12399758-Skin Neoplasms,
pubmed-meshheading:12399758-Tetrahydronaphthalenes,
pubmed-meshheading:12399758-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
|
|
pubmed:affiliation |
Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports,
Research Support, Non-U.S. Gov't
|
